Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy and Autologous PBSC Transplant for Relapsed Pediatric ALL
NCT00002638Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Mar 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine, cytarabine, etoposide and cyclophosphamide in acute lymphoblastic leukemia (ALL), sponsored by University of Nebraska. Primary endpoints: Efficacy of autologous peripheral blood stem cell (PBSC) transplantation for marrow reconstitution at 1 year and Dose effect of autologous PBSC on engraftment at 100 days. Started Mar 1995; status: completed.
02
Drugs
carmustinecytarabineetoposidecyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00002638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002638.